Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).  ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.

"ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes.In addition, it has already demonstrated safety in more than 280 subjects," said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX.  "We hope ITX-5061 will significantly improve long-term transplant outcomes."

The primary objective of the Phase 1b clinical trial will be to assess the safety and tolerability of ITX-5061 in liver transplant patients.  The study will also assess HCV viral load for three months after liver transplantation to determine if ITX-5061 has any immediate and/or sustained impact on viral kinetics in treated patients. Approximately 20 patients will be enrolled into one of two cohorts:  one group will receive supportive care only, while the second cohort will also receive ITX-5061 at a150 mg daily dose for seven days.  The trial is being conducted at the University of Birmingham, UK under the direction of David Mutimer, MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham University and Consultant Hepatologist to the Birmingham QE Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061  may reduce re-infection rates followi
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Amgen ... the submission of a Marketing Authorization Application ... via the centralized procedure for talimogene laherparepvec ... with melanoma that is regionally or distantly ... administered as an intralesional injection that is ...
(Date:9/2/2014)... FRANCISCO, Calif. , Sept. 2, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:9/2/2014)... Redspin, Inc., a leading provider of HIPAA ... an IT security advisory specifically for senior executives in ... presiding over the most dynamic period in the history ... Redspin,s President and CEO. "The goal of our advisory ... understand why they need to elevate IT security to ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:9/2/2014)... Dennis Thompson HealthDay Reporter ... early or at low birth weight are at risk later ... problems that increase their risk for heart disease, according to ... children face potential lifetime disadvantages, researchers in both studies ... found that these obstacles can be overcome. Education appeared ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... Lancet is pleased to announce that the ... presentation at the ESC Congress 2014, taking place ... 2014: , Ultrathin strut biodegradable polymer sirolimus-eluting ... coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, ... design affecting strut thickness, surface polymer, and drug ...
(Date:9/2/2014)... 02, 2014 Eric Jimenez and Leah ... , a revolutionary makeup application device. Designed to improve ... innovation in the palm of women’s hands to help ... to Color Me’s success lies in its patented technology. ... rate of 15,000 pulses per minute, the device applies ...
(Date:9/2/2014)... 02, 2014 With thoughts of getting ... the minds of many Washingtonians, it’s easy to forget ... and office managers to be booking their organizations’ holiday ... Resorts' Washington, DC, area locations are preparing for the ... available for holiday parties, the space appears to be ...
Breaking Medicine News(10 mins):Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 2Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 3Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 4Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 5
... the number of global users outnumbering other users of ... authorities from the U.S have warned that if appropriate ... could lead to a global threat. ,Methamphetamine ... a stimulant that induces euphoria in its users. Discovered ...
... who had been bitten by a bat and subsequently diagnosed with ... observation. Although treatment is being offered, the chances of the boy ... boy, a student of Humble High School fell ill last week, ... weeks before this could happen, a bat had flown into his ...
... a novel study conducted at the University of Illinois at ... happened after the victim was drugged// and in 5% of ... 100,000 sexual assaults are committed in the United States each ... times higher if all cases were reported, said Adam Negrusz, ...
... Queeen's has suggested that patients who combine a low ... better results in clearing toxins and increasing overall physical ... of dialysis patients was recently carried out by Rehabilitation ... and Respiratory (CCR) group at Queen's, and a group ...
... conducted a joint cell and animal study that has revealed ... malaria, often causing death. ,The culprit is a protein ... to suppress red blood cell production in people whose red ... ,The parasite that causes malaria - known as plasmodium - ...
... million American adults are smokers, obese or both and are faced ... // ,Data from a 2002 national health interview ... United States who have one or both problems. ,The ... million people and this would include a larger percentage of them ...
Cached Medicine News:Health News:Meth Addiction On The Rise, US Health Authorities Concerned 2Health News:UIC Study Throws Light On Sexual Assaults 2Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Anemia from Malaria Linked to a Protein MIF 2Health News:Anemia from Malaria Linked to a Protein MIF 3
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: